Singapore-based AI healthcare startup Qritive has raised $7.5 million in a funding round led by MassMutal Ventures, backed by Seeds Capital, the investment arm of Enterprise Singapore, and Exfinity Venture Partners.
The new capital will be used to facilitate geographic expansion, expand the product portfolio and support regulatory approvals.
Founded in 2017 and with offices in San Diego, USA, and Pune, India, Qritive is a provider of AI (artificial intelligence) solutions aimed at advancing digital pathology for cancer diagnosis, improving image accuracy, and improving health outcomes. I am a developer.
The company’s Pantheon digital pathology platform includes tools for aspects such as case management, reporting, slide viewing, and analysis.
@AIHealth1 where a surgery demonstration comes to life with VR.#virtualreality #artificialintelligence #ai #digitalhealth #augmentedreality #aihealth #surgery pic.twitter.com/n5QO97ztuy
— AI Health (@AIHealth1) March 31, 2019
According to Qritive, the goal is to create an environment for open pathology, making cancer diagnosis fast, accurate and affordable.
